2022
DOI: 10.7759/cureus.27775
|View full text |Cite
|
Sign up to set email alerts
|

A Unique Case of Hypothyroidism Causing Pancytopenia With Literature Review

Abstract: Severe endocrinopathies can lead to pancytopenia. Hypothyroidism can affect any organ system including hematopoietic, resulting mainly in a normochromic normocytic anemia. Rarely, in severe hypothyroidism, all hematopoietic cell lines can be affected, resulting in pancytopenia. We, hereby, would like to discuss a case of hypothyroidism with worsening pancytopenia, which gradually improved after repletion with levothyroxine. Although pancytopenia is not a common feature of hypothyroidism, this case highlights t… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3

Citation Types

0
6
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
3

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(6 citation statements)
references
References 12 publications
(9 reference statements)
0
6
0
Order By: Relevance
“…Anifrolumab is Food and Drug Administration-approved for adult patients with moderate-to-severe SLE; however, emerging data suggest it may be a viable option for CLE as well. 2 In a randomized, double-blind, placebo-controlled study of 305 patients with moderate-to-severe SLE, the percentage of patients with a cutaneous lupus erythematosus disease area and severity index score of ≥10 who improved by ≥50% at week 52 was superior with both anifrolumab doses (300 mg: 63%; 1000 mg: 58%) as compared with placebo (31%). 2 Additionally, anifrolumab proved efficacious for patients with refractory CLE in multiple case reports 2 , 3 , 4 , 5 , 6 , 7 and in 2 small prospective studies, 8 , 9 one of which had a patient with CHLE.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…Anifrolumab is Food and Drug Administration-approved for adult patients with moderate-to-severe SLE; however, emerging data suggest it may be a viable option for CLE as well. 2 In a randomized, double-blind, placebo-controlled study of 305 patients with moderate-to-severe SLE, the percentage of patients with a cutaneous lupus erythematosus disease area and severity index score of ≥10 who improved by ≥50% at week 52 was superior with both anifrolumab doses (300 mg: 63%; 1000 mg: 58%) as compared with placebo (31%). 2 Additionally, anifrolumab proved efficacious for patients with refractory CLE in multiple case reports 2 , 3 , 4 , 5 , 6 , 7 and in 2 small prospective studies, 8 , 9 one of which had a patient with CHLE.…”
Section: Discussionmentioning
confidence: 99%
“… 2 In a randomized, double-blind, placebo-controlled study of 305 patients with moderate-to-severe SLE, the percentage of patients with a cutaneous lupus erythematosus disease area and severity index score of ≥10 who improved by ≥50% at week 52 was superior with both anifrolumab doses (300 mg: 63%; 1000 mg: 58%) as compared with placebo (31%). 2 Additionally, anifrolumab proved efficacious for patients with refractory CLE in multiple case reports 2 , 3 , 4 , 5 , 6 , 7 and in 2 small prospective studies, 8 , 9 one of which had a patient with CHLE. This patient with CHLE showed a clinically meaningful improvement by 3 months, consistent with the patients in our case report.…”
Section: Discussionmentioning
confidence: 99%
“…A case of severe hypothyroidism without autoantibodies in a patient who developed pancytopenia has been reported, indicating that hypothyroidism itself can cause pancytopenia regardless of the autoimmune process [9]. Recovery from pancytopenia varies according to reports, ranging from one week to two months with thyroid hormone supplementation [10].…”
Section: Discussionmentioning
confidence: 99%
“…3 Since then, real-world evidence further supports its efficacy in the literature. 1,2,[4][5][6][7][8][9][10][11][12] We present a challenging CHLE case that exhibited rapid response to anifrolumab, along with a literature review on its real-life effectiveness.A 19-year-old Caucasian female presented with a history of paediatric-onset SLE characterized by lymphopenia and positive antinuclear autoimmunity (ANA), antiribonucleoprotein (anti-RNP) and anticardiolipin antibodies. Cryoglobulins and TREX1 mutation tests were negative.…”
mentioning
confidence: 99%
“…3 Since then, real-world evidence further supports its efficacy in the literature. 1,2,[4][5][6][7][8][9][10][11][12] We present a challenging CHLE case that exhibited rapid response to anifrolumab, along with a literature review on its real-life effectiveness.…”
mentioning
confidence: 99%